- Home
- SMTI vs CBIO Comparison
SMTI vs CBIO Comparison
Compare SMTI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- CBIO
- Stock Information
- Founded
- SMTI 1982
- CBIO 2003
- Country
- SMTI United States
- CBIO United States
- Employees
- SMTI N/A
- CBIO N/A
- Industry
- SMTI Medical/Dental Instruments
- CBIO
- Sector
- SMTI Health Care
- CBIO
- Exchange
- SMTI Nasdaq
- CBIO Nasdaq
- Market Cap
- SMTI 251.6M
- CBIO 208.8M
- IPO Year
- SMTI N/A
- CBIO N/A
- Fundamental
- Price
- SMTI $19.54
- CBIO $13.00
- Analyst Decision
- SMTI Strong Buy
- CBIO Strong Buy
- Analyst Count
- SMTI 2
- CBIO 5
- Target Price
- SMTI $50.00
- CBIO $25.60
- AVG Volume (30 Days)
- SMTI 51.2K
- CBIO 68.7K
- Earning Date
- SMTI 11-12-2025
- CBIO 11-06-2025
- Dividend Yield
- SMTI N/A
- CBIO N/A
- EPS Growth
- SMTI N/A
- CBIO N/A
- EPS
- SMTI N/A
- CBIO N/A
- Revenue
- SMTI $101,877,532.00
- CBIO N/A
- Revenue This Year
- SMTI $24.49
- CBIO N/A
- Revenue Next Year
- SMTI $14.43
- CBIO N/A
- P/E Ratio
- SMTI N/A
- CBIO N/A
- Revenue Growth
- SMTI 30.52
- CBIO N/A
- 52 Week Low
- SMTI $19.10
- CBIO $9.81
- 52 Week High
- SMTI $39.08
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- SMTI 20.90
- CBIO 55.88
- Support Level
- SMTI $26.26
- CBIO $12.68
- Resistance Level
- SMTI $29.20
- CBIO $13.45
- Average True Range (ATR)
- SMTI 1.55
- CBIO 0.53
- MACD
- SMTI -0.85
- CBIO 0.06
- Stochastic Oscillator
- SMTI 3.45
- CBIO 70.00
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.